Checkpoint inhibitors are a type of cancer drug that works by removing the brakes on your immune system so it can recognize and attack tumor cells. Unlike chemotherapy, which directly poisons fast-growing cells, checkpoint inhibitors don’t kill cancer themselves. Instead, they block the signals that cancer uses to hide from your body’s T cells, the immune cells responsible for seeking out and destroying threats.
How Checkpoint Inhibitors Work
Your immune system has built-in safety switches called checkpoints. These exist for a good reason: they prevent T cells from attacking your own healthy tissue. Cancer cells exploit this system by producing proteins that flip those switches off, essentially telling T cells to stand down. The tumor looks “normal” to your immune system, so it grows unchecked.
Checkpoint inhibitors are antibodies designed to block that interaction. When the drug prevents the checkpoint protein from connecting with its partner on the tumor cell, the “off” signal never gets sent. T cells reactivate, resume their normal metabolic function, and begin attacking the tumor. This is why checkpoint inhibitors are sometimes described as “releasing the brakes” rather than “pressing the gas.” They don’t supercharge the immune system. They restore what the cancer suppressed.
The Three Main Targets
Most checkpoint inhibitors on the market target one of three proteins: CTLA-4, PD-1, or PD-L1. They work at different stages of the immune response.
CTLA-4 acts early. It regulates T cell activity in the lymph nodes, where immune responses first get organized. Blocking CTLA-4 allows more T cells to activate and multiply in the first place. Ipilimumab, the first checkpoint inhibitor approved (for advanced melanoma), targets this protein.
PD-1 acts later, in the tissues where the tumor actually lives. Cancer cells often produce high levels of a partner protein called PD-L1, which binds to PD-1 on T cells and shuts them down right at the tumor site. Drugs like nivolumab and pembrolizumab block PD-1, preventing this handshake. A separate group of drugs blocks PD-L1 on the tumor side instead, achieving a similar effect.
Because CTLA-4 and PD-1 operate at different points in the immune response, combining drugs that target both can be more effective than using either alone. This dual blockade approach has shown strong results in melanoma and other cancers, sometimes dramatically reducing relapse rates compared to single-drug treatment.
Which Cancers Are Treated
Checkpoint inhibitors were first approved for advanced melanoma and have since expanded to a long list of cancer types. They are now used in non-small cell lung cancer, kidney cancer, bladder cancer, head and neck cancers, certain colorectal cancers, liver cancer, and others. Pembrolizumab alone has approvals across more than a dozen tumor types.
Not every patient with these cancers will receive checkpoint inhibitors. Doctors often test the tumor for specific biomarkers that predict whether the drug is likely to work. The most common biomarkers include PD-L1 expression (how much of the “hide me” protein the tumor produces), microsatellite instability (a sign the tumor has many DNA repair errors, making it more visible to the immune system), and tumor mutational burden (the total number of mutations in the cancer’s DNA). Higher levels of any of these generally signal a better chance of response.
How Treatment Is Given
Checkpoint inhibitors are delivered through an IV infusion, typically at a cancer center or infusion clinic. Early dosing was based on body weight, but most drugs have moved to flat doses for simplicity. Pembrolizumab, for example, is commonly given every three weeks or every six weeks at a fixed dose.
Treatment length depends on the situation. When used after surgery to reduce the chance of recurrence (adjuvant therapy), a standard course lasts about one year. For advanced or metastatic cancers, treatment typically continues for up to two years, or until the cancer progresses or side effects become too severe. There is no strong evidence yet showing that longer courses are better than these standard durations.
How Effective They Are
Checkpoint inhibitors have fundamentally changed survival expectations for several cancers. Before these drugs existed, advanced melanoma had a five-year survival rate in the single digits. A large meta-analysis of clinical trials found that roughly 10% of patients treated with checkpoint inhibitors experience what researchers call a “durable treatment effect,” meaning their cancer remains controlled long-term, well beyond what chemotherapy typically achieves. That 10% figure may sound modest, but in cancers where long-term survival was nearly unheard of, it represents a genuine shift.
Compared to traditional chemotherapy, checkpoint inhibitors generally produce fewer total side effects and a different quality of life during treatment. A meta-analysis comparing PD-1 inhibitors to chemotherapy found significantly fewer adverse events overall with immunotherapy. The tradeoff is that the side effects checkpoint inhibitors do cause are of a fundamentally different nature.
Side Effects to Know About
Because checkpoint inhibitors release the brakes on the immune system broadly, not just at the tumor, they can cause the immune system to attack healthy organs. These are called immune-related adverse events, and they differ sharply from the hair loss, nausea, and low blood counts typical of chemotherapy.
Skin reactions are the most common, affecting up to 50% of patients, though most are mild (rashes, itching). Fatigue, diarrhea, and decreased appetite are also frequent. CTLA-4 inhibitors cause side effects at higher rates and severity than PD-1 or PD-L1 inhibitors: roughly 90% of patients on CTLA-4 drugs experience some adverse event, compared to about 70% on PD-1 drugs.
Most immune-related side effects appear within three to six months of starting treatment, though they can show up as late as a year after exposure. Rarer but serious complications include inflammation of the heart muscle (less than 1% of patients, but potentially fatal), kidney problems (2% to 5%), and severe skin reactions. These are managed by pausing or stopping treatment and using medications that calm the immune response. The key for patients is reporting new symptoms promptly, since early intervention makes a significant difference in outcomes.
Combination Approaches
Checkpoint inhibitors are increasingly used alongside other treatments rather than on their own. Pairing them with chemotherapy is one of the most common strategies. Chemotherapy can make tumors more visible to the immune system by releasing tumor proteins when it kills cancer cells, essentially priming the immune response that the checkpoint inhibitor then unleashes.
In melanoma specifically, combining checkpoint inhibitors with targeted therapies that block specific cancer-driving mutations has shown remarkable results. One trial combining a targeted therapy pair with a PD-1 inhibitor achieved a 100% response rate in melanoma patients and reduced relapse compared to the targeted therapy alone. Dual checkpoint blockade, pairing a CTLA-4 inhibitor with a PD-1 inhibitor, is another well-established combination now used in melanoma, kidney cancer, and lung cancer.
Newer Checkpoint Targets
The current generation of checkpoint inhibitors focuses on CTLA-4, PD-1, and PD-L1, but researchers have identified additional immune checkpoints that tumors exploit. Three proteins receiving the most attention are LAG-3, TIGIT, and TIM-3. One LAG-3-blocking drug, relatlimab, is already being tested in combination with nivolumab in cancers including gastroesophageal cancer. TIGIT inhibitors have shown promising signals in lung cancer when combined with existing PD-L1 drugs, though only in tumors with high PD-L1 expression. These newer targets may eventually expand the number of patients who benefit from immunotherapy, particularly those whose cancers don’t respond well to current options.